Meta-Analysis of SGLT2 Inhibitors on Mortality and Hospitalization in Heart Failure

Xiang Mao's meta-analysis evaluates the impact of SGLT2 inhibitors on clinical outcomes in heart failure patients. It synthesizes data from 15 randomized controlled trials published between 2017 and 2025, encompassing 28,484 participants. The analysis reports hazard ratios for mortality and hospitalization, along with changes in NT-proBNP levels, left ventricular function, and diuretic efficiency.

Use Cases

• Validate the class effect of SGLT2 inhibitors based on pooled hazard ratios for mortality and hospitalization.
• Analyze treatment response heterogeneity across heart failure phenotypes (HFrEF and HFpEF) and diabetes status as described in the results.
• Model the relationship between biomarker changes (NT-proBNP, LVEF) and clinical outcomes using the reported mean differences.
• Benchmark new clinical trial results against the aggregated effect sizes for all-cause mortality and heart failure hospitalization.

Strengths

• Analysis is based on 15 randomized controlled trials with 28,484 total participants, providing a substantial evidence base.
• Follows PRISMA 2020 guidelines and assesses publication bias, suggesting a rigorous methodological approach.
• Reports specific effect sizes with confidence intervals (e.g., HR=0.86 for mortality, HR=0.74 for hospitalization).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for specific analytical tasks.
• The dataset is very small (16.7 KB), indicating it likely contains only summary statistics, not patient-level data.

Provenance

Source

Xiang Mao via figshare.

Collection Method

Systematic review and meta-analysis of RCTs from PubMed, Embase, Cochrane CENTRAL, Scopus, and Web of Science.

Time Range

Studies published between January 2017 and November 2025.

Freshness

Last updated 2026-05-13 04:29:49; freshness should be verified.